Keymed Biosciences Reports First Half 2026 Results
Keymed Biosciences announced on August 19, 2026, its interim results for the six months ended June 30, 2026. The company reported total revenue of RMB 617 million.
CHENGDU, China – Keymed Biosciences (HKEX: 02162) disclosed its interim results on August 19, 2026, for the six-month period ending June 30, 2026. The company reported total revenue of RMB 617 million.
The core product, Kangyueda, generated RMB 393 million in revenue. The company did not provide specific details on sales volumes or unit pricing for the product.
Keymed Biosciences focuses on medical devices and pharmaceuticals. The company is working to expand its product portfolio and market presence.
For the second half of 2026, the company anticipates continued growth and aims to introduce new products and enhance the sales of existing offerings.